Cytochrome P450 2D6 Inhibitor Drug Class List

Drugs in Drug Class: Cytochrome P450 2D6 Inhibitor

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Janssen Biotech	ZYTIGA	abiraterone acetate	TABLET;ORAL	202379-001	Apr 28, 2011	AB	RX	Yes	No
Janssen Biotech	ZYTIGA	abiraterone acetate	TABLET;ORAL	202379-002	Apr 14, 2017	AB	RX	Yes	Yes
Novartis	ZORTRESS	everolimus	TABLET;ORAL	021560-002	Apr 20, 2010	AB	RX	Yes	No
Novartis	ZORTRESS	everolimus	TABLET;ORAL	021560-003	Apr 20, 2010	AB	RX	Yes	No
Novartis	ZORTRESS	everolimus	TABLET;ORAL	021560-004	Aug 10, 2018	AB	RX	Yes	No

Cytochrome P450 2D6 Inhibitor Market Dynamics and Patent Landscape: What Protects Strong CYP2D6 Blockers, When Exclusivity Expires, and Where Generic and Biosimilar Risks Concentrate

Last updated: July 17, 2026

The CYP2D6 inhibitor class is not a single proprietary franchise. Market structure depends on (1) branded “perpetrator” drugs that inhibit CYP2D6 as part of their therapeutic use, (2) dedicated co-therapy programs targeting CYP2D6-drug interaction (DDI) management, and (3) “static” vs “mechanism-based” inhibitor strength that governs DDI magnitude and label language. Patent exposure is typically dispersed: composition, formulation, and use patents for the perpetrator; plus DDI-related method-of-use and dosing regimen claims where sponsors attempted to lock in interaction management.

Which CYP2D6 inhibitors dominate the market and how do dynamics vary by “perpetrator” vs DDI-management strategy?

Featured snippet: Most CYP2D6 inhibition revenue sits in branded therapeutics that inhibit CYP2D6 indirectly through their pharmacology (perpetrator approach). Dedicated DDI management products exist but are a smaller slice of global spend; patent estates usually protect the branded therapeutic drug rather than an isolated “CYP2D6 inhibitor” category product.

Market power drivers for perpetrator drugs (therapeutic-indication led)

1. Indication durability. CYP2D6 inhibitors are embedded in drugs for psychiatry, oncology supportive care, and pain. Indication breadth sustains sales even as DDI awareness increases.
2. Switching costs for prescribers. Label guidance around dose adjustment and monitoring increases physician reliance on established brands.
3. DDI severity stratification. Mechanism-based inhibitors (irreversible or quasi-irreversible in practical terms) generate stronger and longer DDIs than reversible inhibitors, shaping real-world selection.

Market power drivers for dedicated DDI solutions (interaction-led)

1. Regulatory framing. When sponsors position a product for CYP2D6 interaction management, they seek label language that ties dosing schedules to a predictable interaction outcome.
2. Formulation engineering. Controlled-release and dosing regimen patents can matter if they change time above threshold concentrations needed for DDI magnitude.

What patents protect CYP2D6 inhibitors and their CYP2D6-related uses?

Featured snippet: Protection typically covers (a) composition and polymorphs, (b) formulations, (c) method-of-use for therapeutic indications, and (d) sometimes method-of-use that includes CYP2D6-inhibition co-administration and dose adjustment regimens. DDI patents are most likely where sponsors deliberately claimed interaction management in dosing steps.

Patent claim clusters commonly seen in CYP2D6 inhibitor estates

• Active ingredient and salt/crystal forms: broad chemical claims that control generic entry of the base drug.
• Solid-state and polymorph patents: frequently used to extend exclusivity by locking in specific crystalline forms and manufacturing conditions.
• Formulation patents: controlled release, bioavailability, and robustness of exposure for consistent inhibitor concentration.
• Method-of-use patents: include patient populations and co-medication schedules.
• DDI and PK-targeted regimens: claims that recite coadministration with CYP2D6 substrate drugs and specific dose titration/monitoring.

How “mechanism-based” inhibition changes patent strategy

Mechanism-based inhibitors tend to drive:

• Stronger emphasis on pharmacokinetic timing and regimen in method claims.
• Label-mirroring language in dosing patents intended to deter “workaround” regimens that would reduce DDI impact.

When does CYP2D6 inhibitor exclusivity expire and what drives the last mile to generic entry?

Featured snippet: Generic timing is usually determined by the latest-expiring Orange Book-listed patents for the branded perpetrator drug, supplemented by any blocking method-of-use patents and exclusivity periods not listed as patents. DDI-related exclusivity usually tracks the underlying therapeutic drug’s patent life.

The exclusivity stack in practice

1. NCE/505(b)(1) exclusivity (if applicable).
2. Patent term to expiration (including PTA).
3. Orphan exclusivity (rare for CYP2D6 inhibition class overall; depends on specific product).
4. Pediatric exclusivity where triggered.
5. Orange Book-listed blocking patents at filing of ANDA.

“Last blocking patent” dynamics

• Sponsors often focus on a later method-of-use or formulation patent rather than only early composition claims.
• Litigation targets “hard to design around” claims such as specific crystalline forms or dosing regimens tied to PK thresholds.

What Orange Book status patterns appear for branded CYP2D6 inhibitor drugs?

Featured snippet: Orange Book listings for CYP2D6 inhibitors are typically heavy in formulation, polymorph, and method-of-use entries, with a mix of composition-of-matter and use claims. Generic filers typically submit Paragraph IV notices for the most commercially relevant blocking entries.

Orange Book listing patterns to watch

• High “patent density” around dosage forms: tablet strengths, ER beads, or specialized release profiles.
• Multiple exclusivity-linked registrations: multiple patents covering a single NDA through different claimed embodiments.
• Last-expiring use patents: method claims that include coadministration with CYP2D6 substrates.

Which companies are challenging CYP2D6 inhibitor patents, and what does Paragraph IV litigation usually look like?

Featured snippet: Patent challenges in this space concentrate among top generic platforms with established ANDA portfolios and litigation playbooks. Challenges often target the latest-expiring formulation or method-of-use patents rather than early composition claims.

Typical challenger behavior

• Paragraph IV on last-expiring patent to maximize at-risk date.
• Design-around attempts using alternate polymorphs or dosage regimens.
• Waiver and settlement strategy: carve-outs tied to narrow indications or dosage forms.

Settlement patterns affecting DDI status

Where settlements include design-around acceptability, label outcomes can shift:

• A generic may be launched without the DDI-labeled effect if it changes PK exposure or inhibitor strength through formulation changes.
• Sponsors may keep certain language or patient populations tied to the branded perpetrator while accepting generic substitution for narrower conditions.

How strong is the patent estate for CYP2D6 inhibitors: what metrics matter for enforceability and generic deterrence?

Featured snippet: Estate strength is usually highest where the sponsor has (1) multiple blocking patents across composition, solid state, and formulation, and (2) at least one method-of-use claim that is hard to design around. Weakness emerges when the latest-expiring patents are broad and easily circumvented by alternative polymorphs, salts, or release profiles.

Patent strength checklist (practitioner view)

• Breadth of composition claims: covers salts/polymorphs and manufacturing intermediates.
• Solid-state specificity: polymorph claims reduce generic freedom.
• Formulation dependency: ER or dosing schedule claims can block substitution if generic must match exposure profile.
• Method-of-use defensibility: “CYP2D6 inhibition coadministration” claims face design-around by changing dosing sequence unless FDA labeling ties to the claim.
• Litigation history: sustained wins against multiple filers indicates enforceability; repeated adverse rulings suggest vulnerability.

What formulations are protected for CYP2D6 inhibitors, and where are design-arounds most feasible?

Featured snippet: The most common generic design-arounds for CYP2D6 inhibitor perpetrator drugs are switching to different solid-state forms and re-engineering release profiles. These work only if the latest blocking patents do not cover broad ranges of polymorphs or if method claims are not tied to inevitable PK outcomes.

Common formulation patent targets

• Polymorph/crystal form
• Co-crystals
• Salt selection
• Controlled-release beads or matrices
• Particle size and surface area
• Excipients controlling dissolution rate
• Manufacturing process constraints that fix the form and dissolution profile

Design-around feasibility map

• High feasibility: changing crystalline form if claims cover only one polymorph.
• Medium feasibility: matching dissolution and PK in ER systems can be costly but not impossible.
• Low feasibility: if method-of-use claims recite a coadministration regimen that must be followed per label and the PK outcome is hard to alter.

How do CYP2D6 inhibitors affect DDI risk and what does that mean for regulatory and labeling protections?

Featured snippet: Regulatory labeling that describes CYP2D6 inhibitory effects can indirectly protect branded products by tying dosing adjustments to the presence of the inhibitor. Patent protection plus label dependence can raise barriers for generics that cannot match inhibitory exposure.

Label-driven constraints that limit generic substitution

• Dose adjustment instructions for CYP2D6 substrates when coadministered.
• Monitoring language for adverse events for sensitive substrates.
• Contraindication language for high-risk substrate combinations.

FDA review dynamics to watch

• ANDA bioequivalence for the perpetrator drug still controls inhibitor exposure.
• If the generic cannot match systemic exposure, it may be forced into narrower labeling or risk denial of permissive language.

What generic entry risks exist for CYP2D6 inhibitors and when do they materialize?

Featured snippet: Generic entry risk materializes at the combination of (1) Orange Book blocking patent expiration or successful Paragraph IV clearance and (2) readiness to commercialize the full dosage form and labeling required for DDI-relevant use.

Launch sequencing risk points

1. At-risk filing: if the challenger files Paragraph IV before the blocking patent expires.
2. Automatic stay: litigation-triggered stay can delay entry.
3. Settlement-triggered “launch carve-out”: entry may occur later than the theoretical patent date if settlement ties to specific strengths.
4. Reformulation/label changes: generics may launch with narrower DDI language if exposure mismatch forces labeling differences.

How does the patent landscape differ across CYP2D6 inhibitors by therapeutic class?

Featured snippet: Patent density is highest for branded CNS and oncology-supportive drugs where sponsors pursue long-term extensions via formulation and method-of-use. The “DDI effect” is a labeling attribute, so patent life typically mirrors the therapeutic drug’s estate rather than an independent CYP2D6 product category.

CNS and psychiatry-linked CYP2D6 inhibition

• Often see broad method-of-use claims in psychiatric dosing and patient subgroups.
• Formulation patents may focus on exposure stability to reduce concentration spikes that intensify CYP2D6-related interactions.

Oncology supportive care and antiemetic-adjacent DDIs

• Method-of-use patents often include coadministration regimens with CYP-metabolized agents.
• Label dependence can be strong where dosing schedules are standardized by oncology protocols.

Pain and analgesic adjuncts

• Estates frequently include solid-state and dosing regimen patents that lock in controlled exposure.

Side-by-side: how CYP2D6 inhibitor patent estates compare across “perpetrator” brands

Featured snippet: Comparing estates is most useful by aligning (1) latest Orange Book expiration, (2) whether the last patents are formulation/solid-state vs method-of-use, and (3) litigation posture at the time ANDA challengers filed. Estates that end in solid-state patents tend to have fewer generic design-arounds than those ending in broad use claims.

Comparative framework (what to score)

• Latest patent expiration date (including PTA and any litigation-related adjustments)
• Number of Orange Book blocking patents
• Patent types in the last 24-36 months (formulation vs method)
• Claim-by-claim vulnerability based on prior rulings

Key takeaways for R&D, licensing, litigation, and investment decisions

• CYP2D6 inhibition market dynamics are driven by branded perpetrator therapeutics where DDI effects are a labeling attribute, not a standalone commercial category.
• Patent estates are usually strongest where the sponsor controls the late-life stack with formulation and solid-state patents plus at least one DDI-relevant method-of-use claim.
• Generic entry risk is a function of the latest Orange Book blocking patent and the likelihood that a generic can match inhibitory exposure required for the DDI-labeled effect.
• Paragraph IV activity typically targets last-expiring patents that are commercially relevant and hardest to design around.
• In licensing and litigation, the decisive question is rarely “is it a CYP2D6 inhibitor,” it is which exact late-life claims (form, process, or dosing regimen) govern coadministration behavior.

FAQs

1) What patent types most often block ANDA entry for CYP2D6 inhibitor drugs?
Formulation/controlled-release and specific solid-state form patents are most common late-life blockers, followed by method-of-use claims that encode coadministration or dosing adjustments.

2) Do CYP2D6 DDI method-of-use patents survive easier than composition patents?
They often face fewer chemical design-arounds but can be vulnerable if they depend on labeling language that generics can change through exposure matching and FDA labeling negotiation.

3) How do mechanism-based inhibitors change litigation strategy for generic filers?
They drive tighter regimen and PK matching requirements, increasing the difficulty of “practical design-around” strategies that would otherwise reduce inhibitor time above threshold.

4) Can a generic launch without matching the labeled CYP2D6 inhibitory effect?
It can, but success hinges on FDA labeling negotiations and whether bioequivalence achieves the inhibitor exposure required to avoid adverse labeling outcomes tied to CYP2D6 substrate interactions.

5) Where should investors focus when underwriting upside in CYP2D6 inhibitor franchises?
On the latest-expiring, least design-around blocking patents and the litigation/settlement status of the closest ANDA challengers rather than on early composition claim strength.

---

References

No sources were cited in the body; none are listed.